Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 24Recruiting 8Unknown 6Terminated 5Active not recruiting 3Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 86Head & Neck 12Genitourinary 7Thoracic 5Breast 5Gynecologic 4Dermatologic 4Tumor-Agnostic 3Other solid neoplasm 2NET 1Endocrine 1

Conditions

Neoplasms 2Neoplasm Metastasis 1

Interventions

pembrolizumab 18Specimen Handling 9Magnetic Resonance Spectroscopy 9Bevacizumab 8Biopsy 7Paclitaxel 6Nivolumab 6atezolizumab 5Cyclophosphamide 5Surveys and Questionnaires 4Standard of Care 4Practice Guidelines as Topic 4Oxaliplatin 4Ipilimumab 4osimertinib 3niraparib 3durvalumab 3cemiplimab 3avelumab 3X-Rays 3Radiotherapy 3Radiosurgery 3Radiation 3Pemetrexed 3Leucovorin 3Irinotecan 3Interviews as Topic 3Fluorouracil 3Carboplatin 3trastuzumab deruxtecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Fluorouracil × Tumor-Agnostic × Clear all
NCT03203525 2026-02-25

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
38 enrolled
Tumor-Agnostic

Neoplasms

NCT06107413 2025-12-12

Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab

AbbVie

Phase 2 Active not recruiting
280 enrolled
Tumor-Agnostic

Neoplasms

NCT03806309 2025-07-25

TEDOPAM

GERCOR - Multidisciplinary Oncology Cooperative Group

Phase 2 Active not recruiting
106 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡